Case Report | Open Access
Kazushi Yasuda, Eiji Morihana, Naoki Fusazaki, Shiro Ishikawa, "Cardiovascular Malformations in CHARGE Syndrome with DiGeorge Phenotype: Two Case Reports", Case Reports in Pediatrics, vol. 2016, Article ID 8013530, 6 pages, 2016. https://doi.org/10.1155/2016/8013530
Cardiovascular Malformations in CHARGE Syndrome with DiGeorge Phenotype: Two Case Reports
Both CHARGE syndrome and DiGeorge anomaly are frequently accompanied by cardiovascular malformations. Some specific cardiovascular malformations such as interrupted aortic arch type B and truncus arteriosus are frequently associated with 22q11.2 deletion syndrome, while conotruncal defects and atrioventricular septal defects are overrepresented in patients with CHARGE syndrome. CHD7 gene mutation is identified in approximately two-thirds of patients with CHARGE syndrome, and chromosomal microdeletion at 22q11.2 is found in more than 95% of patients with 22q11.2 deletion syndrome. CHARGE syndrome is occasionally accompanied by DiGeorge phenotype. We report two patients with dysmorphic features of both CHARGE syndrome and 22q11.2 deletion syndrome. Although both of the two cases did not have 22q11.2 deletion, they had typical dysmorphic features of 22q11.2 deletion syndrome including cardiovascular malformations such as interrupted aortic arch type B. They also had characteristic features of CHARGE syndrome including ear malformation, genital hypoplasia, limb malformation, and endocrinological disorders. CHD7 gene mutation was confirmed in one of the two cases. When a patient with cardiovascular malformations frequently associated with 22q11.2 deletion syndrome does not have 22q11.2 deletion, we suggest that associated malformations characteristic of CHARGE syndrome should be searched for.
CHARGE syndrome is a pleiotropic disorder, the name of which is derived from the acronym summarizing its six clinical features: ocular coloboma, heart defects, choanal atresia, retardation of growth/development, genital anomalies, and ear anomalies/deafness. CHD7 is the only gene mutation of which is known to cause CHARGE syndrome, and the mutation is identified in approximately two-thirds of patients with a clinical diagnosis of CHARGE syndrome .
DiGeorge anomaly is characterized by thymic deficiency, hypoparathyroidism, and cardiovascular malformation, and it is now recognized that 22q11.2 deletion syndrome encompasses the phenotypes previously described as DiGeorge anomaly . Microdeletion of chromosomal 22q11.2 is found in more than 95% of patients with 22q11.2 deletion syndrome. TBX1, a gene located within the A-B region of chromosome 22q11.2, is responsible for the phenotypic features seen in this syndrome .
The clinical overlap between CHARGE syndrome and 22q11.2 deletion syndrome is recently considered to be more common than anticipated . We here report two patients with dysmorphic features of both CHARGE syndrome and 22q11.2 deletion syndrome and especially describe their cardiovascular malformations.
2. Case Presentation
Case 1. A male fetus was diagnosed as having heart defects and hydramnios at the fetal age of 32 weeks. He was born after 38 weeks of gestation, weighing 2448 g. Shortly after birth, he was admitted to the neonatal intensive care unit and diagnosed as having truncus arteriosus and interrupted aortic arch. Prostaglandin E1 was administered intravenously to maintain the arterial duct patency. Calcium preparation was given because of hypocalcemia, which was subsequently confirmed to be due to hypoparathyroidism.
After transfer to our hospital at 9 days of age, he was diagnosed as having truncus arteriosus type A4, interrupted aortic arch type B, ventricular septal defect, and aberrant origin of the right subclavian artery. He had many dysmorphic features, such as ocular coloboma, choanal atresia, ear anomaly, hearing impairment, thymic deficiency, cleft foot, cleft hand, hockey-stick palmar crease, and distinctive facial features which are square face with broad prominent forehead, “hooded eyelids,” ocular hypertelorism, and micrognathia (Figure 1). He seemed to have both cardiovascular malformations frequently associated with 22q11.2 deletion syndrome and features seen in CHARGE syndrome and/or 22q11.2 deletion syndrome. Fluorescence in situ hybridization analysis did not demonstrate chromosomal microdeletion at 22q11.2, but CHD7 mutation was subsequently confirmed (Table 1). His parents and siblings did not have any chromosomal disorders and anomalies.
At 14 days, he underwent bilateral pulmonary artery banding. Thymic deficiency was confirmed intraoperatively. Flow cytometry of peripheral blood revealed cellular immunodeficiency. A diagnosis of complete DiGeorge anomaly was made, and antimicrobial agents and immunoglobulin were administered.
He was transferred back to the previous hospital for treatment for immunodeficiency at 30 days and underwent cord blood transplantation at 4 months . After successful engraftment, he underwent stent placement for the arterial duct at 10 months.
Case 2. A male neonate was born at the gestational age of 39 weeks, weighing 2794 g. After birth, he was diagnosed as having transient tachypnea of the newborn based on the occurrence of tachypnea and cyanosis. He was also suspected to have hypoplastic aortic arch and hypoplastic left ventricle.
He was referred to our hospital at 6 days of age and diagnosed as having double outlet right ventricle, subpulmonary ventricular septal defect, interrupted aortic arch type B, subaortic stenosis, hypoplastic ascending aorta, aberrant origin of the right subclavian artery, and restrictive atrial septal defect. At 15 days, balloon atrial septostomy was performed. Computed tomography showed additional anomalies of cephalocervical arteries, that is, absence of the right internal carotid artery and the right posterior communicating artery, and aberrant origin of the right external carotid artery from the right subclavian artery and the right vertebral artery directly from the ascending aorta.
At 16 days, he underwent bilateral pulmonary artery banding. No thymus was found intraoperatively, but cellular immunocompetence was subsequently confirmed. He had many other endocrinological disorders and dysmorphic features, that is, hypothyroidism, hypoparathyroidism, ear malformation, hearing impairment, micropenis, cryptorchidism, hockey-stick palmar crease, and distinctive facial features such as square face with broad prominent forehead and prominent nasal bridge (Figure 2). He also seemed to have both cardiovascular malformations frequently associated with 22q11.2 deletion syndrome and many features seen in CHARGE syndrome and/or 22q11.2 deletion syndrome. Fluorescence in situ hybridization analysis did not demonstrate chromosomal microdeletion at 22q11.2 in this patient as well (Table 1). CHD7 gene mutation was not examined. His parents and siblings did not have any chromosomal disorders and anomalies.
At 3 months, he underwent biventricular repair by modified Norwood operation and Rastelli operation, and administration of prostaglandin E1 was discontinued.
22q11.2 deletion syndrome is frequently accompanied by cardiovascular malformations such as conotruncal anomalies (tetralogy of Fallot, truncus arteriosus), interrupted aortic arch, right aortic arch, and aberrant origin of the subclavian artery . In a previous large series, 43% and 34% of patients with 22q11.2 deletion syndrome were found to have interrupted aortic arch type B and truncus arteriosus, respectively. Conversely, 68% of patients with interrupted aortic arch type B and 33% of patients with truncus arteriosus had 22q11.2 deletion syndrome . Therefore, the characteristic pattern of cardiovascular malformations in addition to hypocalcemia and absence of the thymus is likely to lead to early clinical diagnosis of 22q11.2 deletion syndrome.
CHARGE syndrome shows a variety of the combination and extent of symptoms and findings. Immediate evaluations of the airway, feeding, heart, and hearing are required, because multiple life-threatening medical conditions are often found in CHARGE syndrome. Cardiovascular malformations are present in 75% to 85% of individuals with CHARGE syndrome . The severity and spectrum of congenital heart defects had been thought to vary . It is recently reported that conotruncal defects and atrioventricular septal defects are overrepresented in patients with CHD7 mutations compared with patients with nonsyndromic heart defects . Tetralogy of Fallot was relatively frequent among the conotruncal defects, whereas interrupted aortic arch, double outlet right ventricle, and truncus arteriosus were less frequently seen. In contrast to 22q11.2 deletion syndrome, the pattern of cardiovascular malformations is less likely to lead to the diagnosis of CHARGE syndrome.
CHARGE syndrome is rarely accompanied by DiGeorge phenotype without chromosome 22q11.2 deletion . It has long been recognized that CHARGE syndrome and 22q11.2 deletion syndrome have overlapping phenotypic features . The phenotypic similarity between CHARGE syndrome and 22q11.2 deletion syndrome is also apparent in mice with haploinsufficiency of CHD7 and TBX1. Both genes are shown to interact and are required in pharyngeal ectoderm for fourth pharyngeal arch artery development. In addition, both genes are important in development of the thymus and semicircular canals [12, 13].
de Lonlay-Debeney et al. reported that five patients presented with features of both CHARGE syndrome and 22q11.2 deletion syndrome . Four of the five patients had cardiovascular malformations, that is, tetralogy of Fallot, truncus arteriosus, aberrant origin of the left subclavian artery with right aortic arch, and hypoplastic aortic arch with ventricular septal defect, respectively. None of the five patients had chromosome 22q11.2 deletion, similarly to our cases. Recently, Corsten-Janssen and colleagues reported that five patients with a clinical diagnosis of CHARGE syndrome and a proven 22q11.2 deletion were identified . However, 25 of 33 patients with typical 22q11.2 deletion features and a CHD7 mutation had no 22q11.2 deletion. In addition, 5 of 20 patients who were clinically suspected of 22q11.2 deletion syndrome but with neither a 22q11.2 deletion nor a TBX1 gene mutation had a CHD7 mutation. Although the clinical overlap between CHARGE syndrome and 22q11.2 deletion syndrome is recently considered to be more common than anticipated, such overlapping cases seem to be unlikely to have a 22q11.2 deletion, regardless of the high probability of the chromosomal microdeletion in 22q11.2 deletion syndrome.
When a patient with cardiovascular malformations frequently associated with 22q11.2 deletion syndrome does not have 22q11.2 deletion, we suggest that associated malformations characteristic of CHARGE syndrome should be searched for.
The authors declare that there is no conflict of interests regarding the publication of this paper.
- G. E. Zentner, W. S. Layman, D. M. Martin, and P. C. Scacheri, “Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome,” American Journal of Medical Genetics Part A, vol. 152, no. 3, pp. 674–686, 2010.
- L. J. Kobrynski and K. E. Sullivan, “Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes,” The Lancet, vol. 370, no. 9596, pp. 1443–1452, 2007.
- H. Yagi, Y. Furutani, H. Hamada et al., “Role of TBX1 in human del22q11.2 syndrome,” The Lancet, vol. 362, no. 9393, pp. 1366–1373, 2003.
- N. Corsten-Janssen, S. C. Saitta, L. H. Hoefsloot et al., “More clinical overlap between 22q11.2 deletion syndrome and charge syndrome than often anticipated,” Molecular Syndromology, vol. 4, no. 5, pp. 235–245, 2013.
- H. Inoue, H. Takada, T. Kusuda et al., “Successful cord blood transplantation for a CHARGE syndrome with CHD7 mutation showing DiGeorge sequence including hypoparathyroidism,” European Journal of Pediatrics, vol. 169, no. 7, pp. 839–844, 2010.
- K. Momma, “Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome,” American Journal of Cardiology, vol. 105, no. 11, pp. 1617–1624, 2010.
- L. H. S. Van Mierop and L. M. Kutsche, “Cardiovascular anomalies in digeorge syndrome and importance of neural crest as a possible pathogenetic factor,” The American Journal of Cardiology, vol. 58, no. 1, pp. 133–137, 1986.
- K. D. Blake, S. L. H. Davenport, B. D. Hall et al., “CHARGE association: an update and review for the primary pediatrician,” Clinical Pediatrics, vol. 37, no. 3, pp. 159–173, 1998.
- R. K. H. Wyse, S. Al-Mahdawi, J. Burn, and K. Blake, “Congenital heart disease in CHARGE association,” Pediatric Cardiology, vol. 14, no. 2, pp. 75–81, 1993.
- N. Corsten-Janssen, W. S. Kerstjens-Frederikse, G. J. du Marchie Sarvaas et al., “The cardiac phenotype in patients with a CHD7 mutation,” Circulation: Cardiovascular Genetics, vol. 6, no. 3, pp. 248–254, 2013.
- S. Jyonouchi, D. M. McDonald-McGinn, S. Bale, E. H. Zackai, and K. E. Sullivan, “CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features,” Pediatrics, vol. 123, no. 5, pp. e871–e877, 2009.
- V. Randall, K. McCue, C. Roberts et al., “Great vessel development requires biallelic expression of Chd7 and Tbx1 in pharyngeal ectoderm in mice,” The Journal of Clinical Investigation, vol. 119, no. 11, pp. 3301–3310, 2009.
- J. E. H. Bergman, N. Janssen, L. H. Hoefsloot, M. C. J. Jongmans, R. M. W. Hofstra, and C. M. A. van Ravenswaaij-Arts, “CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype,” Journal of Medical Genetics, vol. 48, no. 5, pp. 334–342, 2011.
- P. de Lonlay-Debeney, V. Cormier-Daire, J. Amiel et al., “Features of DiGeorge syndrome and CHARGE association in five patients,” Journal of Medical Genetics, vol. 34, no. 12, pp. 986–989, 1997.
Copyright © 2016 Kazushi Yasuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.